Table 2.
Comparison of features and outcomes of patients with heparin-induced thrombocytopenia before and after HIT e-Consult Service implementation (n = 43).
| Feature | Before, January 1, 2019, to December 31, 2019 (n = 24) | After, February 1, 2021 to January 31, 2022 (n = 19) | t/X2; P value |
|---|---|---|---|
| Demographic information | |||
| Patient age (y), mean (SD) | 57.6 (14.9) | 57.1 (11.7) | 0.11; .91 |
| Patient sex, n (%) | |||
| Male | 11 (46) | 14 (74) | 3.38; .07 |
| Female | 13 (54) | 5 (26) | |
| Patient race, n (%) | |||
| White | 11 (46) | 12 (63) | 1.96; .58 |
| Black | 11 (46) | 6 (32) | |
| Other | 1 (4) | 0 (0) | |
| Unknown | 1 (4) | 1 (5) | |
| Admitting service, n (%) | |||
| Cardiovascular surgery | 9 (37) | 9 (48) | 7.86; <.05 |
| Cardiology (acute care and ICU) | 1 (4) | 5 (26) | |
| Other ICUs (medical, neurologic, and surgical) | 0 (0) | 0 (0) | |
| ECMO | 4 (17) | 0 (0) | |
| Other acute carea | 10 (42) | 5 (26) | |
| Initial anticoagulation, n (%) | |||
| Bivalirudin | 24 (100) | 10 (56) | 13.18; <.001 |
| Oral factor Xa inhibitor | 0 (0) | 6 (33) | |
| Fondaparinux | 0 (0) | 2 (11) | |
| Discharge anticoagulation, n (%) | |||
| Warfarin | 12 (71) | 2 (14) | 10.20; <.01 |
| Oral factor Xa inhibitor | 5 (29) | 11 (79) | |
| Fondaparinux | 0 (0) | 1 (7) | |
| Clinical outcomes | |||
| Incidence of thrombosis, n (%) | 2 (9) | 0 (0) | 1.82; .18 |
| Incidence of major bleeding, n (%) | 3 (14) | 2 (11) | 0.09; .76 |
| Length of stay (d), average (range) | 39 (9-131) | 17 (2-69) | 2.92; <.01 |
Oral factor Xa inhibitors included rivaroxaban and apixaban.
e-consult, electronic consultation; ECMO, extracorporeal membrane oxygenation; HIT, heparin-induced thrombocytopenia; ICU, intensive care unit.
a
Including general surgery, internal medicine (hospitalist), medical oncology, neurology, neurosurgery, orthopedic surgery, trauma, and vascular surgery.